Structure modifying effects of Strontium Ranelate in knee osteoarthritis

Reginster, J. Y., Chapurlat, R., Christiansen, C., Genant, H., Bellamy, N., Benson, W., Navarro, F., Badurski, J., Nasonov, E., Chevalier, X., Sambrook, P. N., Spector, T. and Cooper, C. (2012). Structure modifying effects of Strontium Ranelate in knee osteoarthritis. In: Kanis, J.A. and Lindsay, R., IOF-ECCEO12 European Congress on Osteoporosis and Osteoarthritis, Bordeaux, France, (S58-S59). 21-24 March 2012. doi:10.1007/s00198-012-1923-z

Author Reginster, J. Y.
Chapurlat, R.
Christiansen, C.
Genant, H.
Bellamy, N.
Benson, W.
Navarro, F.
Badurski, J.
Nasonov, E.
Chevalier, X.
Sambrook, P. N.
Spector, T.
Cooper, C.
Title of paper Structure modifying effects of Strontium Ranelate in knee osteoarthritis
Conference name IOF-ECCEO12 European Congress on Osteoporosis and Osteoarthritis
Conference location Bordeaux, France
Conference dates 21-24 March 2012
Journal name Osteoporosis International   Check publisher's open access policy
Place of Publication Surrey, United Kingdom
Publisher Springer
Publication Year 2012
Sub-type Published abstract
DOI 10.1007/s00198-012-1923-z
ISSN 0937-941X
Editor Kanis, J.A.
Lindsay, R.
Volume 23
Issue 2
Start page S58
End page S59
Total pages 2
Language eng
Formatted Abstract/Summary
Objective(s): Strontium ranelate (SrRan) has potential beneficial effects on cartilage degradation in osteoarthritis (OA), stimulating human cartilage matrix formation in vitro and decreasing urinary CTX-II. SrRan has also been shown to reduce radiographic spinal OA progression and back pain in osteoporotic women with prevalent spinal OA. We compared the efficacy and safety of SrRan with placebo in the treatment of knee OA in a double-blind, placebo-controlled, randomised, international 3-year study (registration number: ISRCTN41323372).
Material & Methods: 1683 patients with symptomatic primary knee osteoarthritis and with a Kellgren-Lawrencescore II or III were included and randomly allocated to SrRan 1 or 2 g/day, or placebo. The primary endpoint was radiographic joint space narrowing measured as the mean change from baseline to End in Joint Space Width (JSW) of the knee medial tibiofemoral compartment using a semiautomated centralised reading method. JSW was measured at selection, 12, 24, and 36 months on radiographs acquired using a postero-anterior, weight-bearing, fixed-flexion  acquisition technique (described elsewhere1). Symptoms were primarily assessed by algofunctional WOMAC score and subscores and safety by adverse events and biological parameters.
Results: The intention-to-treat population included 1371 (82%) patients (mean follow-up 29.810.5 months). Mean age was 62.8±7.2 years and 69% were female. Mean BMI was 30±5 kg/m2, mean JSWwas 3.50±0.83 mm, and 61% of randomised patients were Kellgren and Lawrence stage II. Treatment with SrRan was associated with less progression of cartilage degradation, decrease in JSW was -0.230.56 mm with 1 g/day; -0.270.63 mm with 2 g/day and -0.370.59 mm with placebo; treatment-placebo estimated differences (SE) were 0.14 (0.04), p<0.001 for 1 g/day and 0.10 (0.04), p0 0.018 for 2 g/day. SrRan 2 g/day significantly reduced total WOMAC score (p00.045) and pain subscore (p00.028) whereas a trend were observed for physical function subscore (p00.099). SrRan was well tolerated.
Conclusion(s): SrRan 1 and 2 g/day demonstrated a significant beneficial effect on structure in patients with knee OA. This structure-modifying activity was accompanied by symptom improvement at the dosage of SrRan 2 g/day.
Q-Index Code EX
Q-Index Status Provisional Code
Institutional Status UQ

Document type: Conference Paper
Collection: School of Medicine Publications
Version Filter Type
Citation counts: Google Scholar Search Google Scholar
Created: Fri, 22 Jun 2012, 14:46:18 EST by Chesne McGrath on behalf of Medicine - Royal Brisbane and Women's Hospital